Prepress

InkSure and AuthentiForm Announce Assignment of Patent Portfolio

Tuesday 29. January 2008 - Sublicense for Humanitarian Purposes Granted to Global Vaccines

InkSure Technologies Inc. (BULLETIN BOARD: INKS) , a leading provider of covert machine-readable security solutions (“CMRT”) for the detection of counterfeiting, fraud and diversion, and AuthentiForm Technologies, L.L.C., a developer of innovative authentication and item-level identification technologies, today announced that they have entered into an assignment agreement by which InkSure has acquired AuthentiForm’s entire intellectual property portfolio of enhanced product-authentication technology.

The AuthentiForm portfolio includes methods to establish authenticity and identify products at the item level by encoding high information-density, invisible, and essentially tamper-proof signatures within a product’s formulation, on its surface, or through incorporation into its packaging. AuthentiForm technology enables dynamic codes without substantially changing the chemical composition of a product or its components, which makes the AuthentiForm technology particularly attractive for use with pharmaceutical products.

“We have been impressed with AuthentiForm’s developments for some time and believe that its enhanced product identification techniques will be very compatible with a new InkSure product line in development,” commented Yaron Meerfeld, Chief Operating Officer of InkSure Technologies Inc. “Brand owners want more than authentication products: they are looking for solutions,” added Mr. Meerfeld. “We believe that this addition to our authentication and track-and-trace capabilities will offer new and exciting solutions to our portfolio.”

“InkSure emerged as the assignee of choice because of its forward-thinking stance on the technology’s value,” stated AuthentiForm’s Managing Owner Tom Mercolino.

As a further condition of the assignment agreement, InkSure has granted back to AuthentiForm the right to license its portfolio for humanitarian uses. AuthentiForm will sublicense some of the technology’s humanitarian-use rights to Global Vaccines, Inc. (GVI), a non-profit vaccine company. “InkSure has shown its commitment to reducing the insidious effects of counterfeit products by agreeing that AuthentiForm may retain humanitarian-use rights,” Mercolino said. “I am delighted that Global Vaccines will be able to use AuthentiForm to protect its vaccines for people in the developing world.”

“The AuthentiForm technology will help Global fulfill its mission of delivering safe and effective vaccines to the developing world,” said GVI’s Director of Development Jake Wiltshire. “Because it will ensure that people in developing countries are not receiving counterfeit products, it’s a wonderful addition to our existing vaccine portfolio.”